Is It Too Late To Consider AstraZeneca After Its Strong 2025 Share Price Rally?
-
For anyone wondering whether AstraZeneca is still worth considering after its big run or whether the best days are already priced in, this article will walk through what the numbers are really saying about its value.
-
Despite some short term noise, with the share price roughly flat over the last week at -0.4% and over the last month at -0.1%, AstraZeneca is still up 27.5% year to date and 35.1% over the past year. That builds on a 110.3% gain over five years.
-
Those gains have been supported by a steady stream of pipeline and partnership news, from oncology and rare disease advances to new collaborations that expand its reach in cutting edge therapies. Together, these updates have reinforced the market view that AstraZeneca is a…
